Hyderabad: Eye Research Center inaugurated at LVPEI
Hyderabad: A last-generation Ocular Pharmacology Research Center has been created that will focus on ocular pharmacologic research and deepen the complexities of eye diseases, understand the interactions of drugs with pathogens (disease-causing microorganisms) and develop eye care. Will lead in customized treatment for. The inauguration took place at LV Prasad Eye Institute on Friday.
The Center for Pharmacology Ocular Screening, which bears the name of the leading surgeon of Guntur, the late Dr. Chigurupathi Nageswara Rao, former chairman of Granules India Limited, the company supporting this initiative, will encourage collaboration and contribute to educating the public. Enabling the next generation of scientists and medical care providers.
La draw. Samhita Roy, Director, Ocular Pharmacology Investigations, highlighted the Centre’s potential to accelerate progress in ocular pharmacology investigations. The objectives of the center are highlighted, ranging from understanding the therapeutic effects of drugs to perfecting their dosages and creating new drugs for medical treatment.
Uma Devi Chigurupati, Executive Director, Granules India Limited expressed its commitment towards social change: “By supporting LVPEI in setting up this center of pharmaceutical research, we are contributing to the transformation of the society through our innovative research in drug discovery. Are.”
L Dr Prashant Garg, Executive Chairman, LVPEI said, “Dr Chigurupati Nageswara Rao’s Center for Pharmacology Ocular is strategically aligned with LVPEI’s objective of conducting research with a purpose. The research center is uniquely positioned to lead in the administration of medicines for eye care, from laboratory research to practical application in the community and at the bedside. This is an important step towards a better future in pharmaceutical ocular research. “Innovative discoveries made at the center shape the way eye care is done”.
LVPEI, in collaboration with Granules India Limited, will lead a change in the landscape of eye care treatment.
